NEW YORK, NY / ACCESSWIRE / October 1, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
VXRT Shareholders Click Here: https://www.zlk.com/pslra-1/vaxart-inc-information-request-form-2?prid=9722&wire=1
NNOX Shareholders Click Here: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-information-request-form?prid=9722&wire=1
NXTC Shareholders Click Here: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9722&wire=1
* ADDITIONAL INFORMATION BELOW *
Vaxart, Inc. (NASDAQ:VXRT)
VXRT Lawsuit on behalf of: investors who purchased June 25, 2020 - July 25, 2020
Lead Plaintiff Deadline : October 23, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/vaxart-inc-information-request-form-2?prid=9722&wire=1
According to the filed complaint, during the class period, Vaxart, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) Vaxart exaggerated the prospects of its COVID-19 vaccine candidate, including its purported role or involvement in Operation Warp Speed ('OWS'), a program which commits the federal government to massive funding for the development of COVID-19 vaccines; 2) Vaxart's COVID-19 vaccine candidate had no reasonable prospect for mass production and marketing and was not among the companies chosen to receive significant financial support from OWS to produce hundreds of millions of vaccine doses; and 3) Vaxart's COVID-19 vaccine candidate was merely selected to participate in preliminary U.S. government studies to determine potential areas for possible OWS partnership and support.
Nano-X Imaging Ltd. (NASDAQ:NNOX)
NNOX Lawsuit on behalf of: investors who purchased August 21, 2020 - September 15, 2020
Lead Plaintiff Deadline : November 16, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-information-request-form?prid=9722&wire=1
According to the filed complaint, during the class period, Nano-X Imaging Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) Nano-X's commercial agreements and its customers were fabricated; (2) Nano-X's statements regarding its "novel" Nanox System were misleading as the Company never provided data comparing its images with images from competitors' machines; (3) Nano-X's submission to the U.S. Food and Drug Administration admitted the Nanox System was not original; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.
Nextcure, Inc. (NASDAQ:NXTC)
The Nextcure lawsuit was filed on behalf of investors who purchased Nextcure, Inc. (NASDAQ: NXTC) securities: (1) between November 5, 2019 and July 14, 2020, inclusive; and/or (2) pursuant or traceable to the company's secondary public offering declared effective on November 14, 2019.
Lead Plaintiff Deadline : November 20, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nextcure-inc-information-request-form?prid=9722&wire=1
Throughout the class period defendants' statements were materially misleading because the data Defendants possessed on its principle product candidate, NC318, showed a lack of efficacy and objective responses. Had the truth been revealed, the market would have seen that NC318 was not, in fact, effective in treating most tumor types, that the NC318 application was proving to be limited (if even useful at all), and, as a result, there was a significant realizable risk that NC318 would not be nearly as popular as then-existing blockbuster drugs, such as Keytruda.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP